Dr Reddy's expects to launch 25 products in US market in FY21

29 Jun 2020 Evaluate

Dr Reddy's Laboratories is expecting to launch 25 products in the US market in the current financial year (FY21). The drug major has also earmarked a capital expenditure (capex) of Rs 1,000 crore for finding various projects during the ongoing financial year.

Besides, the drug maker is also working on various biosimilar products, including, the Rituximab Phase III trial is progressing as per plan. And, in parallel, it is working on multiple other biosimilar products, which are at different stage of development.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

Dr. Reddys Lab Share Price

6093.85 41.85 (0.69%)
18-Apr-2024 11:05 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1534.70
Dr. Reddys Lab 6093.85
Cipla 1373.00
Zydus Lifesciences 945.10
Lupin 1633.35
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.